NFKB1 and myeloid sarcoma: Researches have been expressing that targeting elements of this pathway is paramount to treating MS, but it is clear that systemic blockage of NF-κB would be unsafe as NF-κB has different effects in different cell types, some of which are protective, some detrimental (Kabashima et al., 2004; Mc Guire et al., 2013).